- Home
- CHRO vs SNPX Comparison
CHRO vs SNPX Comparison
Compare CHRO & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- SNPX
- Stock Information
- Founded
- CHRO 2002
- SNPX 2012
- Country
- CHRO United States
- SNPX United States
- Employees
- CHRO N/A
- SNPX 5
- Industry
- CHRO
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- CHRO
- SNPX Health Care
- Exchange
- CHRO Nasdaq
- SNPX Nasdaq
- Market Cap
- CHRO 4.2M
- SNPX 3.7M
- IPO Year
- CHRO 2024
- SNPX N/A
- Fundamental
- Price
- CHRO $0.60
- SNPX $2.71
- Analyst Decision
- CHRO Strong Buy
- SNPX Strong Buy
- Analyst Count
- CHRO 1
- SNPX 1
- Target Price
- CHRO N/A
- SNPX $14.00
- AVG Volume (30 Days)
- CHRO 121.3K
- SNPX 13.4K
- Earning Date
- CHRO 11-13-2024
- SNPX 11-12-2024
- Dividend Yield
- CHRO N/A
- SNPX N/A
- EPS Growth
- CHRO N/A
- SNPX N/A
- EPS
- CHRO N/A
- SNPX N/A
- Revenue
- CHRO N/A
- SNPX N/A
- Revenue This Year
- CHRO N/A
- SNPX N/A
- Revenue Next Year
- CHRO N/A
- SNPX N/A
- P/E Ratio
- CHRO N/A
- SNPX N/A
- Revenue Growth
- CHRO N/A
- SNPX N/A
- 52 Week Low
- CHRO $0.45
- SNPX $2.32
- 52 Week High
- CHRO $6.00
- SNPX $8.78
- Technical
- Relative Strength Index (RSI)
- CHRO 48.49
- SNPX 45.01
- Support Level
- CHRO $0.55
- SNPX $2.52
- Resistance Level
- CHRO $0.71
- SNPX $2.80
- Average True Range (ATR)
- CHRO 0.10
- SNPX 0.21
- MACD
- CHRO -0.00
- SNPX -0.01
- Stochastic Oscillator
- CHRO 23.98
- SNPX 33.32
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.